Significant Agreements - Novo Nordisk Share Purchase Agreement (Details) - USD ($) |
1 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Jul. 08, 2021 |
Dec. 31, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
Accounts receivable | $ 0 | $ 5,159,000 | ||
Novo Nordisk | ||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
Accounts receivable | 0 | 0 | ||
Share Purchase Agreement, Upfront Payment | $ 60,000,000 | |||
Share Purchase Agreement, Potential Payment Upon Achievement of Development and Sales Milestones | 1,130,000,000 | |||
Revenue from License and Intellectual Property, Share Purchase Agreement | $ 0 | $ 0 | ||
Milestone achievement, Clinical milestone | $ 40,000,000 | |||
Novo Nordisk | Transition services | ||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
Revenue from License and Intellectual Property, Share Purchase Agreement | $ 700,000 |